The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Stephen B. Willingham, Jens Peter Volkmer, Andrew J. Gentles, Debashis Sahoo, Piero Dalerba, Siddhartha S. Mitra, Jian Wang, Humberto Contreras-Trujillo, Robin Martin, Justin D. Cohen, Patricia Lovelace, Ferenc A. Scheeren, Mark P. Chao, Kipp Weiskopf, Chad Tang, Anne Kathrin Volkmer, Tejaswitha J. Naik, Theresa A. Storm, Adriane R. Mosley, Badreddin EdrisSeraina M. Schmid, Chris K. Sun, Mei Sze Chua, Oihana Murillo, Pradeep Rajendran, Adriel C. Cha, Robert K. Chin, Dongkyoon Kim, Maddalena Adorno, Tal Raveh, Diane Tseng, Siddhartha Jaiswal, Per Øyvind Enger, Gary K. Steinberg, Gordon Li, Samuel K. So, Ravindra Majeti, Griffith R. Harsh, Matt De Van Rijn, Nelson N.H. Teng, John B. Sunwoo, Ash A. Alizadeh, Michael F. Clarke, Irving L. Weissman

Research output: Contribution to journalArticlepeer-review

682 Scopus citations

Abstract

CD47, a "don't eat me" signal for phagocytic cells, is expressed on the surface of all human solid tumor cells. Analysis of patient tumor and matched adjacent normal (nontumor) tissue revealed that CD47 is overexpressed on cancer cells. CD47 mRNA expression levels correlated with a decreased probability of survival formultiple types of cancer. CD47 is a ligand for SIRPα, a protein expressed on macrophages and dendritic cells. In vitro, blockade of CD47 signaling using targeted monoclonal antibodies enabled macrophage phagocytosis of tumor cells that were otherwise protected. Administration of anti-CD47 antibodies inhibited tumor growth in orthotopic immunodeficient mouse xenotransplantation models established with patient tumor cells and increased the survival of the mice over time. Anti-CD47 antibody therapy initiated on larger tumors inhibited tumor growth and prevented or treated metastasis, but initiation of the therapy on smaller tumors was potentially curative. The safety and efficacy of targeting CD47 was further tested and validated in immune competent hosts using an orthotopic mouse breast cancer model. These results suggest all human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination. These data, taken together with similar findings with other human neoplasms, show that CD47 is a commonly expressed molecule on all cancers, its function to block phagocytosis is known, and blockade of its function leads to tumor cell phagocytosis and elimination. CD47 is therefore a validated target for cancer therapies.

Original languageEnglish (US)
Pages (from-to)6662-6667
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number17
DOIs
StatePublished - Apr 24 2012
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors'. Together they form a unique fingerprint.

Cite this